Quality
A research compound is only as good as the documentation behind it. The BIOMOD release panel is built around purity verification, identity confirmation, content assay, elemental impurities, bacterial endotoxins, and sterility — applied uniformly to every research peptide lot through an independent third-party laboratory. The standards below are the standards on the page. They are also the standards on the Certificate of Analysis.
The release panel
The full BIOMOD release panel.
Every BIOMOD research peptide is tested by High-Performance Liquid Chromatography with UV/VIS detection to confirm chromatographic purity. The BIOMOD release specification is 99%+ purity. Lots that fail to meet this specification are not released into the catalog. The chromatogram is captured on the Certificate of Analysis.
Peptide identity is confirmed through chromatographic profile, retention time, and supporting mass-spectrometric review. Identity verification protects against substitution and confirms that the released peptide matches its declared sequence.
Every BIOMOD research peptide lot is tested for elemental impurities by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). The panel covers the four elemental impurities most relevant to research peptide chemistry — arsenic, cadmium, lead, and mercury — at limits of quantification down to 0.005 ppm. ICP-MS is the analytical method specified under USP <233> for elemental impurities testing.
Every BIOMOD research peptide lot is tested for bacterial endotoxins using the Limulus Amebocyte Lysate (LAL) assay. The BIOMOD release specification is < 5.00 EU/mg, consistent with the USP/FDA pharmacopeial threshold of 5 EU/kg. Endotoxin control is a critical impurity test for any lyophilized peptide intended for downstream injectable research applications.
Every BIOMOD research peptide lot is tested for sterility under United States Pharmacopeia chapter <71>, the compendial sterility test. Lots are released only against a Pass — No Growth Detected result. Compendial sterility testing on every lot is not standard practice across the research peptide category. BIOMOD applies it as the floor.
Third-party verification
Operational discipline
Every BIOMOD product carries a lot number that links directly to its specific Certificate of Analysis. The lot system allows researchers to trace any vial, softgel batch, or spray batch back to its synthesis or manufacturing record and to the specific test results for that lot.
BIOMOD invested in formulation development before scaling its product catalog. pH ranges, buffering systems, vehicle composition, and reconstitution behavior were evaluated against stability targets and refined in-house. That work informed our spray product vehicles and our softgel delivery system — the foundation of the World’s First Peptide Softgel™ line.
Lyophilized research peptides are frozen at the point of manufacture and held at −20 °C through fulfillment. In lyophilized form, peptides remain stable through normal ambient transit, and BIOMOD has validated this across thousands of shipments. Upon receipt, lyophilized peptides should be returned to freezer storage until reconstitution. Softgels and spray products are produced with a 2-year shelf life and held in temperature-controlled storage prior to dispatch.
BIOMOD Softgels are manufactured in California. BIOMOD Spray Products are manufactured in Las Vegas, Nevada. BIOMOD Research Peptides are finished — that is, lyophilized and lot-coded — at our Las Vegas facility. Any imported finished goods, where used, are sourced from FDA-registered partner facilities.
All BIOMOD products are labeled and sold strictly for laboratory research use only. They are not intended for human or animal consumption. BIOMOD does not provide dosing, medical, therapeutic, diagnostic, or use guidance under any circumstances.
All BIOMOD sales are final. The single exception is identity or purity disagreement. If a researcher submits a BIOMOD lot to an independent third-party laboratory and the resulting report returns identity or purity results materially inconsistent with BIOMOD’s published Certificate of Analysis for that lot, BIOMOD will issue a full refund upon review of the third-party report. This standard places verification on equal footing for both the buyer and the company.
COA reference
COA reference
Method
What it confirms
Chromato-graphic Purity
HPLC-UV/VIS
Peptide is 99%+ pure with minimal related impurities.
Assay
HPLC-UV/VIS
Measured peptide content matches the label claim.
Arsenic (As)
ICP-MS · LOQ 0.01 ppm
Elemental impurity within release specification.
Cadmium (Cd)
ICP-MS · LOQ 0.01 ppm
Elemental impurity within release specification.
Lead (Pb)
ICP-MS · LOQ 0.02 ppm
Elemental impurity within release specification.
Mercury (Hg)
ICP-MS · LOQ 0.005 ppm
Elemental impurity within release specification.
Bacterial Endotoxins
LAL
Below the USP/FDA threshold of 5 EU/kg.
Sterility
USP
No microbial growth detected. Pharmacopeial sterility.
Each COA additionally carries: laboratory ID, lot number, sample weight, reporting analyst, operations approval, and reporting date.
